The group's principal activities are to develop and market prescription pharmaceutical products for the treatment of gastrointestinal disease that affect digestive tract. The group uses third-party manufacturers to produce material for use in clinical trials and for commercial product. The group's first marketed product, colazal is approved by the food and administration for the treatment of mildly to moderately active ulcerative colitis and the first new oral therapy approved by the fda for this indication. In Nov 2003, the group acquired the right to sell 25, 75 and 100 milligram dosage strengths of azathioprine tablets in North America under the brand name azasan. Azasan is a drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. The group currently markets colazal and two dosage strengths of azasan.
